We are thrilled to announce that all investigator sites participating in the Pear 2.0 clinical trial, aimed at demonstrating the efficacy of RITI® RA, have been officially established. ✅
To learn more about the Pear 2.0 clinical trial and its progress: https://t.co/hfKdDbnGRu
Un grand merci à la @bfc_region pour son soutien à travers la subvention #PassExport, qui a permis à mYXpression de participer à la @festofbiologics en juin dernier ! 🌍✨ Cette expérience a été un véritable tremplin pour l'expansion de l'entreprise à l'échelle mondiale.
Thanks to the sequencing of the patient's #RNA, mYXpression will identify with great precision the over-expressed biomarkers involved in inflammation. This information is crucial to target the most effective #biotherapy for a patient with #rheumatoidarthritis.
Several studies have demonstrated that rapid and effective treatment offers better chances of #remission for patients with #rheumatoid arthritis. The time factor is crucial in managing this pathology, and RITI® addresses this need.
Wiam Belkacemi - Product manager at mYXpression
Several years ago, mYXpression patiently built up the most complete integrated #transcriptomic#data sets of autoimmune and inflammatory diseases 📊 To know more 👉🔗https://t.co/FvNUhdL8Oi
🔬 Célébrons la première Journée Nationale de la Bioproduction de Biomédicaments en France ! 🌿
Pour découvrir comment la bioproduction et les biomédicaments façonnent l'avenir de la médecine : https://t.co/RTnJbE4Muc
Découvrez le parcours inspirant d'Elodie Dumay-Pauthenet, Responsable Administrative et Ressources Humaines chez mYXpression, dans notre dernier article 🔗 https://t.co/7EP8krxeuX
Autoimmune diseases represent a major medical challenge, affecting millions of people worldwide. The key to effectively managing these diseases lies in the rapid identification of the appropriate treatment.
#innovation#Autoimmunediseases#treatment
1st day at #BIO 2024 !
“The Bio International Convention is an exceptional opportunity to highlight the significant progress we have made in the field of personalized medicine. 𝗚𝗲𝗼𝗿𝗴𝗲𝘀-𝗜𝗴𝗼𝗿 𝗖𝗵𝗮𝗴𝘃𝗮𝗿𝗱𝗶𝗲𝗳𝗳, Business Development at mYXpression.
By providing unprecedented profiling of patient subpopulations and generating precise predictions about their likelihood of responding to a medication, mYXpression ensures optimized patient recruitment for your #clinicaltrial.
To learn more : https://t.co/7eOTzQMSdg
🧬 Meet us at BIO2024 🧬
Are you planning to attend the BIO International Convention 2024 from June 3 to 6 in San Diego, California? Send us a message at [email protected]. #Bio2024
🎙️Jean-François Prugnot, directeur général de mYXpression, sera présent lors du prochain congrès Printemps de l'IA le 20 juin prochain à Besançon pour une table ronde sur le retour d'expérience sur l'implémentation de l'IA en PME ! 🔗https://t.co/xezw1oUUZ6
We are thrilled to announce that mYXpression will be participating in the upcoming BIO International Convention from June 3rd to June 6th, 2024, in San Diego! @IAmBiotech
C'est officiel, certaines biothérapies administrées par voie sous-cutanée dans le traitement de maladies inflammatoires chroniques peuvent être désormais initiées en ville par les médecins spécialistes concernés 🔗 https://t.co/MTWsSqYp80 @ansm
🔍 [Biomédicaments] Optimiser le recrutement des patients dans les essais cliniques grâce à l'IA prédictive. Pour plus d'informations 🔗https://t.co/BxCV5rh2mI
#biomedicaments#IA#etudeclinique
🌟 [Biopharmaceuticals] Optimizing Patient Recruitment in Clinical Trials with Predictive AI 🌟
For more information 🔗https://t.co/7eOTzQMSdg
#AI#Recruitment#ClinicalTrials